<p>Avaii Wealth Management LLC 在最近向證券交易委員會（SEC）提交的文件中表示，在第三季度將其在百時美施貴寶公司（NYSE:BMY - 免費報告）的持股減少了 81.7%。該公司在此期間出售了 66,729 股後，持有 14,992 股該生物製藥公司的股票。根據其最近的 SEC 文件，Avaii Wealth Management LLC 在百時美施貴寶的持股價值為 676,000 美元。</p>
<p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
<ul>
<li>為什麼 GRAIL 股票可能是生物技術的下一個重大突破</li>
</ul>
<p>其他幾家機構投資者也對該股票的持倉進行了調整。Advocate Group LLC 在第三季度將其在百時美施貴寶的持倉提高了 1.5%。Advocate Group LLC 目前持有 156,594 股該生物製藥公司的股票，價值 7,062,000 美元，此前在上個季度增持了 2,355 股。Nicholas Wealth LLC 在第三季度將其在百時美施貴寶的股份增加了 31.0%。Nicholas Wealth LLC 目前持有 31,247 股該生物製藥公司的股票，價值 1,409,000 美元，此前增持了 7,394 股。Allspring Global Investments Holdings LLC 在第三季度將其在百時美施貴寶的持倉提高了 81.1%。Allspring Global Investments Holdings LLC 目前持有 970,647 股該生物製藥公司的股票，價值 46,038,000 美元，此前增持了 434,745 股。Merit Financial Group LLC 在第三季度將其在百時美施貴寶的持倉提高了 27.1%。Merit Financial Group LLC 目前持有 52,673 股該生物製藥公司的股票，價值 2,376,000 美元，此前增持了 11,238 股。最後，Consilium Wealth Advisory LLC 在第三季度新購入了百時美施貴寶的股份，價值約 927,000 美元。目前 76.41% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師評級調整</h2>
<p>多位分析師對該股票發表了看法。BMO Capital Markets 在 11 月 17 日的報告中重申了對百時美施貴寶股票的 “市場表現” 評級。滙豐銀行在 12 月 10 日的研究報告中重申了 “持有” 評級，並設定了 53.00 美元的目標價。花旗集團在 11 月 17 日的研究報告中將百時美施貴寶的目標價從 48.00 美元下調至 45.00 美元，並對該股票設定了 “中性” 評級。富國銀行在 12 月 10 日的報告中將百時美施貴寶的目標價從 53.00 美元上調至 55.00 美元，並給予該公司 “等權重” 評級。最後，摩根士丹利在 12 月 12 日的研究報告中重申了 “減持” 評級，並對百時美施貴寶的股票設定了 37.00 美元的目標價（之前為 36.00 美元）。六位研究分析師對該股票給予了買入評級，十四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，共識目標價為 54.62 美元。</p>
<ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
<p><strong>閲讀我們關於百時美施貴寶的最新報告</strong></p>
<h2>百時美施貴寶股票表現</h2>
<p>百時美施貴寶（NYSE:BMY）週四開盤價為 53.93 美元。百時美施貴寶公司的一年最低價為 42.52 美元，一年最高價為 63.33 美元。該公司的 50 日移動平均價格為 49.42 美元，200 日移動平均價格為 47.43 美元。公司當前比率為 1.27，速動比率為 1.17，債務與股本比率為 2.39。該股票的市值為 1,097.9 億美元，市盈率為 18.22，市盈率/增長比率為 8.30，貝塔值為 0.29。</p>
<ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近在 10 月 30 日宣佈了其季度財報。這家生物製藥公司報告本季度每股收益為 1.63 美元，超出分析師的共識預期 1.52 美元，超出幅度為 0.11 美元。百時美施貴寶的股本回報率為 76.53%，淨利潤率為 12.57%。該公司本季度的收入為 122.2 億美元，而分析師預期為 117.5 億美元。在去年同期，該公司每股收益為 1.80 美元。百時美施貴寶的收入同比增長了 2.8%。百時美施貴寶已將其 2025 財年的指引設定為 6.400-6.600 美元每股收益。股票分析師預測百時美施貴寶公司本年度每股收益將達到 6.74 美元。</p>
<h2>百時美施貴寶增加股息</h2>
<p>該公司最近還披露了季度股息，將於 2 月 2 日（星期一）支付。1 月 2 日的登記投資者將獲得每股 0.63 美元的股息。除息日期為 1 月 2 日。這比百時美施貴寶之前的季度股息 0.62 美元有所增加。這相當於年化股息為 2.52 美元，股息收益率為 4.7%。百時美施貴寶的股息支付比率為 83.78%。</p>
<h2>百時美施貴寶簡介</h2>
<p>（免費報告）</p>
<p>百時美施貴寶是一家全球生物製藥公司，總部位於新澤西州普林斯頓，專注於發現、開發和提供針對嚴重疾病的藥物。公司的核心業務包括在多個治療領域進行處方藥的研究與開發、臨牀開發、生產和商業化。BMS 專注於通過小分子和生物製劑推進腫瘤學、血液學、免疫學、心血管疾病和特殊領域的治療。</p>
<p>BMS 的市場產品組合和後期管線反映了對癌症和免疫介導疾病的強烈關注。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過百時美施貴寶</li>
<li>這個假期你花的第一美元是最值得的</li>
<li>假期驚喜：1 美元讓你擁有一切</li>
<li>美國 “最糟糕” 的聖誕促銷</li>
<li>市場恐慌：特朗普剛剛對你的股票投下了一顆炸彈</li>
<li>你家族的財富將在 2026 年到期？</li>
</ul>
<p><strong>想看看其他對百時美施貴寶持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取百時美施貴寶公司（NYSE:BMY - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
<p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

百時美施貴寶

<p>Avaii Wealth Management LLC 在第三季度減少了對百時美施貴寶公司（NYSE:BMY）81.7% 的持股，目前持有 14,992 股，價值 67.6 萬美元。其他機構投資者也調整了他們的持倉，Advocate Group LLC 增加了 1.5% 的股份，而 Allspring Global Investments Holdings LLC 則提升了 81.1% 的持股。分析師對該股票的評級意見不一，普遍評級為 “持有”，目標價為 54.62 美元。百時美施貴寶報告第三季度每股收益為 1.63 美元，超出預期，營收為 122.2 億美元，同比增長 2.8%</p>

<p>Avaii Wealth Management LLC decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 81.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,992 shares of the biopharmaceutical company's stock after selling 66,729 shares during the period. Avaii Wealth Management LLC's holdings in Bristol Myers Squibb were worth $676,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Avaii Wealth Management LLC 在最近向證券交易委員會（SEC）提交的文件中表示，在第三季度將其在百時美施貴寶公司（NYSE:BMY - 免費報告）的持股減少了 81.7%。該公司在此期間出售了 66,729 股後，持有 14,992 股該生物製藥公司的股票。根據其最近的 SEC 文件，Avaii Wealth Management LLC 在百時美施貴寶的持股價值為 676,000 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 GRAIL 股票可能是生物技術的下一個重大突破</li>
</ul>
</div><p>Several other institutional investors have also made changes to their positions in the stock. Advocate Group LLC lifted its position in Bristol Myers Squibb by 1.5% during the 3rd quarter. Advocate Group LLC now owns 156,594 shares of the biopharmaceutical company's stock worth $7,062,000 after acquiring an additional 2,355 shares during the last quarter. Nicholas Wealth LLC. increased its stake in shares of Bristol Myers Squibb by 31.0% in the third quarter. Nicholas Wealth LLC. now owns 31,247 shares of the biopharmaceutical company's stock worth $1,409,000 after purchasing an additional 7,394 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Bristol Myers Squibb by 81.1% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 970,647 shares of the biopharmaceutical company's stock worth $46,038,000 after purchasing an additional 434,745 shares during the last quarter. Merit Financial Group LLC boosted its stake in Bristol Myers Squibb by 27.1% during the 3rd quarter. Merit Financial Group LLC now owns 52,673 shares of the biopharmaceutical company's stock valued at $2,376,000 after purchasing an additional 11,238 shares during the period. Finally, Consilium Wealth Advisory LLC acquired a new stake in Bristol Myers Squibb in the 3rd quarter valued at approximately $927,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家機構投資者也對該股票的持倉進行了調整。Advocate Group LLC 在第三季度將其在百時美施貴寶的持倉提高了 1.5%。Advocate Group LLC 目前持有 156,594 股該生物製藥公司的股票，價值 7,062,000 美元，此前在上個季度增持了 2,355 股。Nicholas Wealth LLC 在第三季度將其在百時美施貴寶的股份增加了 31.0%。Nicholas Wealth LLC 目前持有 31,247 股該生物製藥公司的股票，價值 1,409,000 美元，此前增持了 7,394 股。Allspring Global Investments Holdings LLC 在第三季度將其在百時美施貴寶的持倉提高了 81.1%。Allspring Global Investments Holdings LLC 目前持有 970,647 股該生物製藥公司的股票，價值 46,038,000 美元，此前增持了 434,745 股。Merit Financial Group LLC 在第三季度將其在百時美施貴寶的持倉提高了 27.1%。Merit Financial Group LLC 目前持有 52,673 股該生物製藥公司的股票，價值 2,376,000 美元，此前增持了 11,238 股。最後，Consilium Wealth Advisory LLC 在第三季度新購入了百時美施貴寶的股份，價值約 927,000 美元。目前 76.41% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of analysts have weighed in on the stock. BMO Capital Markets reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. HSBC reaffirmed a &#34;hold&#34; rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Citigroup decreased their target price on Bristol Myers Squibb from $48.00 to $45.00 and set a &#34;neutral&#34; rating on the stock in a research report on Monday, November 17th. Wells Fargo &amp; Company upped their price target on Bristol Myers Squibb from $53.00 to $55.00 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, December 10th. Finally, Morgan Stanley reiterated an &#34;underweight&#34; rating and issued a $37.00 price objective (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Six research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and a consensus price target of $54.62.</p>
<div class="lb-trans"><p>多位分析師對該股票發表了看法。BMO Capital Markets 在 11 月 17 日的報告中重申了對百時美施貴寶股票的 “市場表現” 評級。滙豐銀行在 12 月 10 日的研究報告中重申了 “持有” 評級，並設定了 53.00 美元的目標價。花旗集團在 11 月 17 日的研究報告中將百時美施貴寶的目標價從 48.00 美元下調至 45.00 美元，並對該股票設定了 “中性” 評級。富國銀行在 12 月 10 日的報告中將百時美施貴寶的目標價從 53.00 美元上調至 55.00 美元，並給予該公司 “等權重” 評級。最後，摩根士丹利在 12 月 12 日的研究報告中重申了 “減持” 評級，並對百時美施貴寶的股票設定了 37.00 美元的目標價（之前為 36.00 美元）。六位研究分析師對該股票給予了買入評級，十四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，共識目標價為 54.62 美元。</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
</div><p><strong>Read Our Latest Report on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於百時美施貴寶的最新報告</strong></p>
</div><h2>Bristol Myers Squibb Stock Performance</h2>
<div class="lb-trans"><h2>百時美施貴寶股票表現</h2>
</div><p>Shares of NYSE:BMY opened at $53.93 on Thursday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The business has a 50-day moving average price of $49.42 and a two-hundred day moving average price of $47.43. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. The stock has a market capitalization of $109.79 billion, a P/E ratio of 18.22, a P/E/G ratio of 8.30 and a beta of 0.29.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY）週四開盤價為 53.93 美元。百時美施貴寶公司的一年最低價為 42.52 美元，一年最高價為 63.33 美元。該公司的 50 日移動平均價格為 49.42 美元，200 日移動平均價格為 47.43 美元。公司當前比率為 1.27，速動比率為 1.17，債務與股本比率為 2.39。該股票的市值為 1,097.9 億美元，市盈率為 18.22，市盈率/增長比率為 8.30，貝塔值為 0.29。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.22 billion during the quarter, compared to analysts' expectations of $11.75 billion. During the same period in the prior year, the business posted $1.80 EPS. Bristol Myers Squibb's revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近在 10 月 30 日宣佈了其季度財報。這家生物製藥公司報告本季度每股收益為 1.63 美元，超出分析師的共識預期 1.52 美元，超出幅度為 0.11 美元。百時美施貴寶的股本回報率為 76.53%，淨利潤率為 12.57%。該公司本季度的收入為 122.2 億美元，而分析師預期為 117.5 億美元。在去年同期，該公司每股收益為 1.80 美元。百時美施貴寶的收入同比增長了 2.8%。百時美施貴寶已將其 2025 財年的指引設定為 6.400-6.600 美元每股收益。股票分析師預測百時美施貴寶公司本年度每股收益將達到 6.74 美元。</p>
</div><h2>Bristol Myers Squibb Increases Dividend</h2>
<div class="lb-trans"><h2>百時美施貴寶增加股息</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Friday, January 2nd. This is a boost from Bristol Myers Squibb's previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.7%. Bristol Myers Squibb's dividend payout ratio is 83.78%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，將於 2 月 2 日（星期一）支付。1 月 2 日的登記投資者將獲得每股 0.63 美元的股息。除息日期為 1 月 2 日。這比百時美施貴寶之前的季度股息 0.62 美元有所增加。這相當於年化股息為 2.52 美元，股息收益率為 4.7%。百時美施貴寶的股息支付比率為 83.78%。</p>
</div><h2>Bristol Myers Squibb Profile</h2>
<div class="lb-trans"><h2>百時美施貴寶簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.</p>
<div class="lb-trans"><p>百時美施貴寶是一家全球生物製藥公司，總部位於新澤西州普林斯頓，專注於發現、開發和提供針對嚴重疾病的藥物。公司的核心業務包括在多個治療領域進行處方藥的研究與開發、臨牀開發、生產和商業化。BMS 專注於通過小分子和生物製劑推進腫瘤學、血液學、免疫學、心血管疾病和特殊領域的治療。</p>
</div><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p>
<div class="lb-trans"><p>BMS 的市場產品組合和後期管線反映了對癌症和免疫介導疾病的強烈關注。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>The Best $1 You'll Spend This Holiday Season</li>
<li>Holiday surprise: $1 gets you everything</li>
<li>America’s “most deplorable” Christmas sale</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
<li>Your family's wealth expires in 2026?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過百時美施貴寶</li>
<li>這個假期你花的第一美元是最值得的</li>
<li>假期驚喜：1 美元讓你擁有一切</li>
<li>美國 “最糟糕” 的聖誕促銷</li>
<li>市場恐慌：特朗普剛剛對你的股票投下了一顆炸彈</li>
<li>你家族的財富將在 2026 年到期？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BMY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對百時美施貴寶持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取百時美施貴寶公司（NYSE:BMY - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Avaii Wealth Management LLC 持有百時美施貴寶公司價值 67.6 萬美元的股票